IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

The Effects of the Tumor Mass Size Inoculated in Immunologically Competent Balb/c Mice on Delayed-type Hypersensitivity Response

정상 면역 생쥐에 접종된 암세포주의 종괴 형성이 숙주의 지연성과민반응에 미치는 영향

  • Lim, Hyun-Ja (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine) ;
  • Woo, A-Mi (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine) ;
  • Jung, Young-Ju (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine) ;
  • Kang, Jae-Seung (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine) ;
  • Shin, Dong-Hoon (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine) ;
  • Lee, Wang-Jae (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine) ;
  • Hwang, Young-Il (Department of Anatomy and Tumor Immunity Medical Research Center, Seoul National University College of Medicine)
  • 임현자 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터) ;
  • 우아미 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터) ;
  • 정영주 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터) ;
  • 강재승 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터) ;
  • 신동훈 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터) ;
  • 이왕재 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터) ;
  • 황영일 (서울대학교 의과대학 해부학교실, 종양면역의학과학센터)
  • Published : 2006.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Based on outstanding progresses in animal experiments, vaccines for some human tumors have been developed. However, clinical effects of these vaccines have been far below than expected. This discrepancy might come from differences between animal models and human patients with respect to immunocompetency. The immune status of mice after tumor inoculation has not been well studied, which make us cautious in interpreting and applying the results from mice to human. We evaluated cell-mediated immune responses in mice after tumor cell inoculation. Methods: Mice were inoculated with TA3Ha, CT26, or 4T1. Delayed-type hypersensitivity (DTH) responses were induced 2-4 weeks after inoculation using 2,4-dinitro-1-fluorobenzene as an antigen. The relationships between the severity of DTH responses and the duration of tumor inoculation or the size of tumor mass were analyzed. Results: In T A3Ha groups, DTH response was elevated 2 weeks after inoculation, but depressed after 4 weeks, compared to the control group. When analyzed based on the sizes of tumor masses elicited, DTH responses were inversely related to the mass size, especially in those greater than 10 mm in diameter. In CT26 groups, while the duration after inoculation did not affect the severity of DTH responses, those with large mass showed depressed responses regardless the duration of inoculation. 4T1 cells grew so slowly that the size of tumor mass was small even 4 weeks after inoculation, and this group showed much higher DTH responses compared to that of tumor-free group. Conclusion: At least in an experimental setting where tumor model was induced by inoculating tumor cell lines into immunologically competent mice, the host immune response was elevated in early stage, and then depressed in late stage when the mass grew over a critical size.

Keywords

References

  1. Old LJ: Tumor immunology: the first century. Curr Opin Immunol 4;603-607, 1992 https://doi.org/10.1016/0952-7915(92)90034-C
  2. Minev BR, Chavez FL, Mitchell MS: Cancer vaccines: novel approaches and new promise. Pharmacol Ther 81;121-139, 1999 https://doi.org/10.1016/S0163-7258(98)00039-4
  3. Moingeon P: Cancer vaccines. Vaccine 19;1305-1326, 2001 https://doi.org/10.1016/S0264-410X(00)00372-8
  4. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T: Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51;45-52, 2002 https://doi.org/10.1007/s00262-001-0255-1
  5. Jennings GT, Bachmann MF: Immunotherapies: cause for measured optimism. Drug Discov Today 7;994-996, 2002 https://doi.org/10.1016/S1359-6446(02)02443-1
  6. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mule JJ: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8;1021-1032, 2002
  7. Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV:Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 105;41-50, 2006 https://doi.org/10.3171/jns.2006.105.1.41
  8. Kim R, Emi M, Tanabe K, Arihiro K: Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66;5527-5536, 2006 https://doi.org/10.1158/0008-5472.CAN-05-4128
  9. Malmberg KJ: Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53;879-892, 2004
  10. Lindauer M, Stanislawski T, Haussler A, Antunes E, Cellary A, Huber C, Theobald M: The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes. J Mol Med 76;32-47, 1998 https://doi.org/10.1007/s109-1998-8102-9
  11. Perez-Diez A, Marincola FM: Immunotherapy against antigenic tumors: a game with a lot of players. Cell Mol Life Sci 59;230-240, 2002 https://doi.org/10.1007/s00018-002-8419-5
  12. McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE: Aspects of cancer immunotherapy. Immunol Cell Biol 81;79-85, 2003 https://doi.org/10.1046/j.0818-9641.2002.01140.x
  13. Morris EC, Bendle GM, Stauss HJ: Perspects for immunotherapy of malignant disease. Clin Exp Immunol 131;1-7, 2003 https://doi.org/10.1046/j.1365-2249.2003.02055.x
  14. Buchanan KL, Murphy JW: Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayedtype hypersensitivity reaction. Immunology 90;189-197, 1997 https://doi.org/10.1046/j.1365-2567.1997.00144.x
  15. Kobayashi K, Kaneda K, Kasama T: Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53;241-245, 2001 https://doi.org/10.1002/jemt.1090
  16. Roychowdhury S, Svensson CK: Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J 7;E834-E846, 2005 https://doi.org/10.1208/aapsj070480
  17. Dhabhar FS, McEwen BS: Stress-induced enhancement of antigen-specific cell-mediated immunity. J Immunol 156;2608-2615, 1996
  18. Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M, Migliori G, Riccobon A: Improved overall survival in dendritic cell vaccination-induced immunoreactive sub group of advanced melanoma patients. J Transl Med 4;36, 2006 https://doi.org/10.1186/1479-5876-4-36
  19. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M: Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. J Immunol 163;2387-2391, 1999
  20. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S: Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64;2205-2211, 2004 https://doi.org/10.1158/0008-5472.CAN-03-2646
  21. Salvadori S, Martinelli G, Zier K: Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164;2214-2220, 2000 https://doi.org/10.4049/jimmunol.164.4.2214
  22. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E:Tumor-derived CD4(+) CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 13 [Epub]; 2006
  23. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R: Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 59;2950-2956, 1999
  24. Barbieri C, Fujisawa MM, Yasuda CL, Metze IL, Oliveira EC, Santos LM, Lopes LR, Andreollo NA: Effect of surgical treatment on the cellular immune response of gastric cancer patients. Braz J Med Biol Res 36;339-345, 2003
  25. Kempuraj D, Devi RS, Madhappan B, Conti P, Nazer MY, Christodoulou S, Reginald J, Suthinthirarajan N, Namasivayam A: T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopathol Pharmacol 17;57-64, 2004